Revenue distribution by sectors:

• Pharmaceuticals: approx. 85%
• Biotechnology: approx. 10%
• Other: approx. 5%

TOP 3 markets and their percentage shares:

• Japan: approx. 55%
• USA: approx. 25%
• Europe: approx. 15%

Chugai Pharmaceutical Co., Ltd. generates the majority of its revenue from the pharmaceutical sector, with a focus on the development and marketing of innovative drugs. The domestic market of Japan remains the largest revenue driver, followed by the USA and Europe, which are also significant markets for the company. These markets benefit from strong demand for specialized medications and the strategic partnership with Roche, which supports international distribution.

Production Sites:

• Japan (main production sites)
• Overseas production facilities in Asia and Europe

Chugai Pharmaceutical Co., Ltd. produces the majority of its products in Japan, where the main production sites are located. These sites specialize in the manufacturing of pharmaceutical products and biotechnological goods. Additionally, the company operates production facilities in other Asian countries and Europe to better serve international demand. This strategic distribution enables Chugai to efficiently respond to global market requirements and minimize supply chain risks.

Focus on Research and Development: 20% of revenue (2024)

Expansion of Global Presence: Partnerships in Europe and the USA (2024)

Innovative Therapies: Focus on oncology and rare diseases (2024)

Chugai Pharmaceutical Co., Ltd. is pursuing a growth strategy that heavily emphasizes research and development. In 2024, the company invested approximately 20% of its revenue in this area to expand its pipeline of innovative drugs. The focus is on developing new therapies in the fields of oncology and rare diseases, which are considered high-growth segments in the pharmaceutical market.

In addition, Chugai aims to expand its global presence, particularly through strategic partnerships in Europe and the USA. These collaborations are intended to facilitate access to new markets and strengthen international competitiveness.

Through these strategic measures, Chugai aims to solidify its position as a leading biopharmaceutical company and achieve sustainable growth.

Main raw materials: Biopharmaceutical active ingredients, chemicals for drug manufacturing

Countries of origin: USA, Germany, Switzerland, China

Chugai Pharmaceutical Co., Ltd. is a leading biopharmaceutical company specializing in the development and production of innovative drugs. For the production of their medications, Chugai imports various biopharmaceutical active ingredients and chemical components. These materials are essential for drug manufacturing and are mainly sourced from the USA and European countries such as Germany and Switzerland, known for their highly developed pharmaceutical industry.

In addition, Chugai also sources raw materials from China, which is a significant supplier of chemical raw materials. The selection of supplier countries is based on the availability of high-quality materials and existing trade relationships.

Market Share in Japan: 10% (2024, estimate)
R&D Expenditure: 20% of revenue (2023)
Patents: Over 7,000 active patents (2023)

Chugai Pharmaceutical Co., Ltd. has a significant competitive advantage, especially due to its strong R&D orientation. With R&D expenditures accounting for 20% of revenue, the company invests heavily in the development of new drugs and therapies. This allows Chugai to bring innovative products to the market and stand out from competitors.

Another advantage is the extensive patent portfolio with over 7,000 active patents. This protects the company from imitators and ensures long-term revenue streams. Additionally, Chugai benefits from the strategic partnership with Roche, which facilitates access to global markets and enables synergies in research.

The market share of about 10% in Japan demonstrates the company's strong position in the domestic market. Together, these factors give Chugai a sustainable competitive advantage in the pharmaceutical industry.

Institutional investor share: approx. 60% (estimate based on 2023 data)

Insider purchases/sales: No significant transactions in the last year (estimate based on 2023 data)

The institutional investor share in Chugai Pharmaceutical Co., Ltd. typically stands at around 60%, indicating the trust of major financial institutions in the company. These investors play a crucial role in the stability and long-term growth of the company.

Regarding insider purchases or sales, there have been no significant transactions in the last year. This suggests that the management and other insiders are currently not making significant changes to their stake in the company, indicating a stable confidence in the company's future development.

Market share of Chugai Pharmaceutical Co., Ltd.: 7% (estimated for 2025)

Main competitors and their market shares:

1. Roche Holding AG: 15%
2. Novartis AG: 12%
3. Sanofi: 10%
4. Pfizer Inc.: 9%
5. AstraZeneca: 8%
6. Chugai Pharmaceutical Co., Ltd.: 7%
7. Bristol-Myers Squibb: 6%
8. Merck & Co., Inc.: 5%
9. GlaxoSmithKline: 4%
10. Eli Lilly and Company: 3%

Chugai Pharmaceutical Co., Ltd. is a significant player in the pharmaceutical market, especially due to its close connection with Roche, which as the majority shareholder represents a strategic partnership. This relationship provides Chugai with access to global resources and research networks, which can be considered a key part of their moat.

Compared to other companies, Chugai has a solid, but not insurmountable moat. Roche and Novartis have stronger global distribution networks and more extensive research and development resources, giving them an advantage. However, Chugai's specialization in oncology and biopharmaceuticals offers some protection and differentiation in the market.

Competition in the pharmaceutical sector is intense, and while Chugai has specific strengths, they must continuously invest in innovation and partnerships to maintain and expand their market share.

Revenue Growth: 8.5% (2024) Research and Development Ratio: 18% of revenue (2024) Market Share in Japan: 12% (2024)

Chugai Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2024, attributed to a strong product pipeline and successful launches of new drugs. The company continuously invests in research and development, allocating 18% of its revenue to this area. This indicates strong innovative capabilities that can secure long-term competitive advantages.

Chugai holds a significant market share of 12% in the Japanese pharmaceutical market, highlighting its strong position in one of the world's largest pharmaceutical markets. This market position enables the company to benefit from the aging population and increasing demand for medical solutions.

Overall, Chugai Pharmaceutical could present an attractive investment opportunity, especially for investors focusing on long-term growth and innovation in the healthcare sector. The strong focus on research and development as well as the solid market position are positive indicators of future growth potential.

Dividend yield: 2.1% (2025, estimated)
Dividend history: Continuous payout in the last 5 years

Chugai Pharmaceutical Co., Ltd. regularly pays dividends to its shareholders. The dividend yield for the year 2025 is estimated to be around 2.1%. Over the past five years, the company has pursued a consistent dividend policy, indicating a reliable payout.

Chugai is known for its strong financial position and its ability to generate stable earnings. This supports the continuous payment of dividends. The reliability of the payout is further strengthened by the stable business model and the strategic partnership with Roche.